Latest News

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 5, 2026.

Phase 2b PROCEED trial results and a phase 1 drug interaction study for bocunebart were presented at AHS 2026, collectively strengthening the drug's development case as a first-in-class PACAP-targeting therapy.

As the MS community reflects on World MS Day, Alla Wilson, a clinical ambulatory pharmacist at Shields Health Solutions, discusses how integrated specialty pharmacy models can improve treatment access, adherence, and patient-reported outcomes for multiple sclerosis.

European regulators have expanded atogepant’s label to include acute migraine treatment, supported by phase 3 data showing significant pain freedom and sustained relief versus placebo.

The assistant professor of neurology at NYU Grossman School of Medicine discussed how optical coherence tomography can support the 2024 McDonald Criteria for multiple sclerosis at CMSC 2026.

12-montn interim findings from an ongoing phase 1/2 study showed up to 69% reductions in mutant huntingtin protein and favorable cUHDRS trends with the investigational oral RNA-splicing modifier SKY-0515.

Kyle Blackburn, MD, a neurologist at UT Southwestern Medical Center, discussed new proposed updates to the diagnostic criteria and nosology for myelitis presented at the 2026 CMSC Annual Meeting.

Updated clinical data highlight opakalim’s ongoing development in epilepsy, with pivotal focal epilepsy results expected later this year.

CMSC 2026 registry data showed low relapse rates and no new safety signals among adults with AQP4-positive NMOSD treated with eculizumab or ravulizumab in real-world practice.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is mmoldering inflammation in MS!

Christina Xia, MD, a stroke specialist at Cleveland Clinic, reviewed recent advances in stroke rehabilitation, including neuromodulation and emerging approaches aimed at improving long-term recovery after stroke.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 29, 2026.

New data presented at CMSC 2026 suggest ocrelizumab provides comparable relapse and MRI control in pediatric- and young-adult–onset multiple sclerosis, with greater disability improvement observed in pediatric patients.